PUBLIC COMPANY
save$SNDXSyndax Pharmaceuticals Inc
$SNDX17.60-3.40%New York, NY, USupdated 1d ago
community read0 votes
pipeline
2
marketed
1
phase 3
0
catalysts ytd
1
approvals ytd
0
recalls ytd
0
Pipeline(2)
pipeline depth2 products
1Marketed1Unknown
Upcoming
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase1A Study of Revumenib in Combination With Intensive Chemotherapy in Participants With Acute Myeloid Leukemias
- phase2A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
- phase3Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation
- phase2A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD)
- phase2MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF)
- phase2Evaluation of Revumenib in Participants With Colorectal Cancer and Other Solid Tumors
- phase2A Phase 1/2 Study to Evaluate Axatilimab in Participants With Active cGVHD
- —Expanded Access Program for Revumenib
🐶 Hiring Signal
next earnings Nov 2, 2026
News
- Kura spins diabetes work into a Lilly-backed biotech startupCaspian Therapeutics aims to develop menin inhibitors, which have proven effective against leukemia, for diabetes and other cardiometabolic conditions.biopharma_dive · 24d ago
- Kura creates Lilly-backed spinout armed with $50M to advance next-gen diabetes therapyKura Oncology has spun out a biotech armed with $50 million in fresh funding to take forward a next-generation diabetes treatment.fiercebiotech · 24d ago
Data sources
last refreshed 1m ago
Found something off?
comments(0)
5-min edit window · permanent after that